- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02895412
Infection and Tumour Antigen Cellular Therapy (INTACT-WT1)
A Clinical Trial of Donor-derived WT1 Specific T Cells for Prevention of Relapse in Combination With Multiple Pathogen Specific T Cells for Prevention of Infection in Patients Undergoing Allogeneic Haemopoietic Stem Cell Transplant for AML
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New South Wales
-
Westmead, Sydney, New South Wales, Australia, 2145
- Recruiting
- Westmead Hospital
-
Contact:
- Gililan Huang
- Phone Number: +61 2 9845 7219
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients undergoing myeloablative or non-myeloablative allogeneic transplantation from an HLA (A, B and DR) identical or 1-3 antigen mismatched family or unrelated donor
- Transplant performed for acute myeloid leukaemia
- Leukaemia blasts express the WT1 tumour antigen as determined by the European LeukaemiaNet standardised assay described in 16. WT1 overexpression will be defined by greater than 250 copies/104ABL copies in bone marrow samples or greater than 50 copies/104ABL copies in peripheral blood. This assay will be performed on samples collected as part of routine clinical care at diagnosis and during initial treatment prior to transplantation. Testing will be performed after consent for trial participation has been obtained and negativity for WT1 will be classified as screening failure
- Recipients of peripheral blood HSCT
- Adequate hepatic and renal function (< 3 x upper limit of normal for AST, ALT, < 2 x upper limit of normal for total bilirubin, serum creatinine)
- Estimated life expectancy of at least 12 months
- Patient (or legal representative) has given informed consent
Exclusion Criteria:
- Use of anti-lymphocyte globulin (ALG, ATG, Campath or other broad spectrum lymphocyte antibody) given in the 4 weeks immediately prior to infusion or planned within 4 weeks after infusion
- Grade II or greater graft versus host disease within 1 week prior to infusion
- Prednisone or methylprednisone at a dose of > 1 mg/kg (or equivalent in other steroid preparations) administered within 72 hours prior to cell infusion
- Prior allogeneic HSCT
- Privately insured in or outpatients (see Indemnity Issues, Section 11.4)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Transplant Recipient
The T cell product administration is personalized cellular therapy product, individually prepared for each participant. Donor-derived WT1-CTL and P-CTL. It's exact make up and effect is dependent on both donor and recipient characteristics and as such variability is expected in the response. These variations will be adjusted for by multiple samplings over time and collation and analysis of response in both individuals an the group as a whole. One infusion of 2 x 107/m2 P-CTLs prophylactically on or after day 28 post-allogeneic peripheral blood haemopoietic stem cell transplant (HSCT), combined with up to four infusions of 2x107/m2 WT1-CTLs. |
Donor-derived WT1-CTL and P-CTL. P-CTL will be given prophylactically a minimum of 28 days after transplantation followed by administration of monthly infusions of WT1-CTL for up to four doses. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: 2 Years
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
|
2 Years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- INTACT-WT1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia, Myelocytic, Acute
-
GlaxoSmithKlineCompletedLeukaemia, Myelocytic, AcuteUnited States
-
GlaxoSmithKlineTerminatedLeukaemia, Myelocytic, AcuteUnited States, Australia, Canada
-
Jewish General HospitalThe Leukemia and Lymphoma SocietyCompletedAcute Myelocytic LeukemiaCanada
-
Hebei Senlang Biotechnology Inc., Ltd.Hebei Yanda Ludaopei HospitalUnknownAcute Myelocytic LeukemiaChina
-
Gruppo Italiano Malattie EMatologiche dell'AdultoUnknown
-
Anhui Provincial HospitalRecruitingAcute Myelocytic LeukemiaChina
-
The Affiliated Hospital of the Chinese Academy...Unknown
-
Grupo Cooperativo de Estudio y Tratamiento de las...Completed
-
Pierian BiosciencesDiaTech Oncology and Vanderbilt UniversityCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
Clinical Trials on Donor-derived WT1-CTL and P-CTL
-
University College, LondonDeutsche Krebshilfe e.V., Bonn (Germany); European Union; The Leukemia and Lymphoma... and other collaboratorsTerminatedAcute Lymphoblastic LeukemiaUnited Kingdom, Germany
-
University Hospital, Basel, SwitzerlandNot yet recruitingEBV Lymphoma | Post-transplant Lymphoproliferative Disease (PTLD)Switzerland
-
Catherine BollardActive, not recruiting
-
Xuzhou Medical UniversityUnknownRenal Cell Carcinoma
-
CatalYm GmbHRecruitingSolid Tumor, AdultSpain, Germany, Switzerland
-
Gary DoolittleCompleted
-
Shenzhen Geno-Immune Medical InstituteShenzhen Children's Hospital; Shenzhen Hospital of Southern Medical UniversityUnknown
-
Shenzhen University General HospitalRecruitingMalignant TumorChina
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedGlioblastoma Multiforme | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma | Gliomas | Anaplastic Mixed Glioma | Malignant MeningiomaUnited States
-
National Institute of Diabetes and Digestive and...CompletedLymphoproliferative Disorders | Liver DiseaseUnited States